首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症癌症診斷

市場調查報告書

商品編碼

1533606

癌症診斷市場規模、佔有率和成長分析：按產品、技術、應用、最終用戶和地區分類 - 產業預測，2024-2031 年

Cancer Diagnostics Market Size, Share, Growth Analysis, By Product, By Technology, By Application, By End User, By Region - Industry Forecast 2024-2031

出版日期: 2024年08月06日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

癌症診斷市場價值將於 2022 年達到 1,123 億美元，高於 2023 年的 1,200.4 億美元，預測期內（2024-2031 年）複合年成長率為 6.89%，到 2031 年將達到 2,045.5 億美元。美元。

癌症診斷涉及識別不同的細胞類型、蛋白質和癌性腫瘤存在的指標。該行業的成長是由全球癌症發病率上升、早期檢測意識增強、癌症研究和開發資金增加、診斷測試技術進步以及私人診斷中心數量增加所推動的。根據SkyQuest的詳細分析，預計2024年將出現約2,001,140名新癌症患者，將對癌症診斷市場產生直接影響。此外，醫療支出的增加和政府的支持措施也促進了市場的成長。然而，高資本成本、高輻射暴露可能性以及缺乏熟練專業人員等挑戰也會影響市場。由於醫療基礎設施的改善和政府促進癌症篩檢的努力，亞太地區等新興地區正在經歷快速成長。此外，遠端醫療和行動醫療應用程式等數位健康技術的採用正在增強遠端監控和個人化護理。然而，高成本、監管挑戰和資料隱私問題仍然是充分挖掘市場潛力需要解決的主要挑戰。

市場概況
消耗品
- 抗體
- 套件/試劑
- 探測
- 其他消耗品
裝置
- 病理學設備
玻片染色系統
組織處理系統
細胞處理器
PCR設備
NGS設備
微陣列
其他基於病理學的設備
- 影像設備
CT系統
超音波系統
核磁共振系統
乳房X光攝影系統
核子造影系統
- 切片檢查儀器

全球癌症診斷市場：依技術分類

市場概況
體外診斷測試
- 聚合酵素鏈鎖反應
- 原位雜合反應
- 免疫組織化學
- 次世代定序
- 免疫檢測
- 微陣列
- 流式細胞技術
- 其他體外診斷技術
成像技術
- 磁振造影
- 電腦斷層掃描
- 核子造影
- 乳房X光照相術
- 超音波
切片檢查

全球癌症診斷市場：依應用分類

市場概況
乳癌
肺癌
大腸直腸癌
惡性黑色素瘤
其他癌症

全球癌症診斷市場：依最終用戶分類

市場概況
醫院
診斷實驗室
其他

全球癌症診斷市場規模：按地區分類

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Abbott Laboratories（US）
Agilent Technologies（US）
Becton, Dickinson and Company（BD）（US）
bioMerieux SA（France）
Danaher Corporation（US）
F. Hoffmann-La Roche Ltd.（Switzerland）
GE Healthcare（US）
Hologic, Inc.（US）
Illumina, Inc.（US）
Koninklijke Philips NV（Netherlands）
Merck KGaA（Germany）
Myriad Genetics, Inc.（US）
QIAGEN NV（Netherlands）
Siemens Healthineers AG（Germany）
Sysmex Corporation（Japan）
Thermo Fisher Scientific Inc.（US）
Exact Sciences Corporation（US）
Guardant Health, Inc.（US）
Caris Life Sciences（US）
Foundation Medicine, Inc.（US）

簡介目錄

Product Code: SQMIG35J2078

Cancer Diagnostics Market was valued at USD 112.3 Billion in 2022 and is expected to rise from USD 120.04 Billion in 2023 to reach a value of USD 204.55 Billion by 2031, at a CAGR of 6.89% during the forecast period (2024-2031).

Cancer diagnostics involves identifying various cell types, proteins, and indicators that signal the presence of cancerous tumors. The growth in this field is largely driven by the increasing global incidence of cancer, heightened awareness of early detection, increased funding for cancer research and development, technological advancements in diagnostic testing, and a rise in private diagnostic centers. According to SkyQuest's detailed analysis, around 2,001,140 new cancer cases are expected in 2024, which will have a direct impact on the cancer diagnostics market. Furthermore, rising healthcare expenditure and supportive government initiatives are contributing to market growth. Despite this, challenges such as significant capital costs, potential high radiation exposure, and a shortage of skilled professionals also affect the market. Emerging regions like Asia-Pacific are experiencing rapid growth due to improvements in healthcare infrastructure and government initiatives promoting cancer screening. Additionally, the adoption of digital health technologies, including telemedicine and mobile health apps, is enhancing remote monitoring and personalized care. However, high costs, regulatory challenges, and data privacy concerns remain major issues to address in order to fully leverage the market potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Diagnostics Market Segmental Analysis

The cancer diagnostics market is segmented based on the Product, Technology, Application, End User and region. Based on the Product, the cancer diagnostics market is segmented into Consumables (Antibodies, Kits & Reagents, Probes, Others) and Instruments (Pathology-Based Instruments [Slide Staining Systems, Tissue Processing Systems, Cell Processors, PCR Instruments, NGS Instruments, Microarrays, Others], Imaging Instruments [CT Systems, Ultrasound Systems, MRI Systems, Mammography Systems, Nuclear Imaging Systems], Biopsy Instruments). Based on the Application, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, and Others. Based on the Technology, the market is segmented into IVD Testing (Polymerase Chain Reaction, In Situ Hybridization, Immunohistochemistry, Next-Generation Sequencing, Immunoassay, Microarray, Flow Cytometry, Others), Imaging Technologies (Magnetic Resonance Imaging, Computed Tomography, Nuclear Imaging, Mammography, Ultrasound), and Biopsies. Based on the End User, the market is segmented into Hospitals, Diagnostic Laboratories, Others. Based on Region it is categorized into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa.

Drivers of the Global Cancer Diagnostics Market

Growing government initiatives to promote the benefits of early diagnosis are expected to drive significant growth in the cancer diagnostics market in the near future. In developing and underdeveloped regions, awareness and availability of cancer diagnostic products are relatively low. To address this issue, both private and government organizations are launching awareness campaigns to educate the public about the importance of early diagnosis.

Restraints in the Global Cancer Diagnostics Market

Exposure to radiation from CT scans and X-rays poses health risks, including an increased likelihood of developing serious conditions such as cancer. These potential side effects can lead to decreased patient compliance and acceptance of radiation therapy, which may, in turn, impact the overall use of radiation in cancer diagnosis and treatment.

Market Trends of the Global Cancer Diagnostics Market

The interest in early cancer detection through simple blood tests, known as liquid biopsies, is rapidly growing. These tests offer a less invasive alternative to traditional diagnostic methods and have been gaining traction for their potential to identify cancer at an early stage. Recent research indicates that blood tests, which analyze various markers including genes and proteins, could be sensitive enough to diagnose cancer. This emerging diagnostic approach holds promise for improving early detection and potentially enhancing treatment outcomes.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Supply Chain Analysis
Patent Analysis
Trade Analysis
Ecosystem of the Market
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Global Cancer Diagnostic Market by Product

Market Overview
Consumables
- Antibodies
- Kits & Reagents
- Probes
- Other Consumables
Instruments
- Pathology-Based Instruments
Slide Staining Systems
Tissue Processing Systems
Cell Processors
PCR Instruments
NGS Instruments
Microarrays
Other Pathology-Based Instruments
- Imaging Instruments
CT Systems
Ultrasound Systems
MRI Systems
Mammography Systems
Nuclear Imaging Systems
- Biopsy Instruments

Global Cancer Diagnostic Market By Technology

Market Overview
IVD Testing
- Polymerase Chain Reaction
- In Situ Hybridization
- Immunohistochemistry
- Next-Generation Sequencing
- Immunoassay
- Microarray
- Flow Cytometry
- Other IVD Technologies
Imaging Technologies
- Magnetic Resonance Imaging
- Computed Tomography
- Nuclear Imaging
- Mammography
- Ultrasound
Biopsies

Global Cancer Diagnostic Market By Application

Market Overview
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Other Cancers

Global Cancer Diagnostic Market By End User

Market Overview
Hospitals
Diagnostic Laboratories
Others

Global Cancer Diagnostic Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Abbott Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (BD) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bioMerieux SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Koninklijke Philips N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Caris Life Sciences (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Foundation Medicine, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments